Drugs / Withaferin A
Withaferin A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05610735 | Sep 2024 → Nov 2027 expected | ovarian cancer | Sham Sunder Kakar | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07708987 | Sep 2023 → Jan 2028 expected | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Tata Memorial Centre | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Withaferin A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07708987 ↗ |
| Known as | NSC-101088 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517080 ↗ |
| Known as | NSC-273757 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517080 ↗ |
| Known as | SWA | “What is standardized Withaferin-A (SWA)? Withaferin-A (WA) is the principal active component of Withania somnifera (Ashwagandha).” NCT07708987 ↗ |
| Action | Inhibit | “WA inhibited NF-κB nuclear translocation in lymphocytes” PMID 26408225 ↗ Sep 2015 |
| Modality | Traditional medicine (herbal / TCM) | “Withaferin-A (WA), an active principle obtained from a traditional Indian herb known as Ashwagandha or the Indian ginseng” PMID 30904387 ↗ Mar 2019 |
| Route | Oral | “Route of administration: Per-oral (P/O)” NCT07708987 ↗ |